Full Press Release Details
Kamada Strengthens Senior Leadership
Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma Derived Therapeutics Market
Rehovot, Israel, and Hoboken, NJ, June 15,
2022 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived
therapeutics, announced today the promotions of Shavit Beladev to Vice President responsible for the Company's Plasma Operations, and
Boris Gorelik to Vice President of Business Development and Strategic Programs, both reporting to Kamada's CEO, Amir London. Ms. Beladev
will be responsible for the operations and expansion of Kamada Plasma, the Company's wholly owned U.S-based plasma collection subsidiary.
Mr. Gorelik will be responsible for the advancement of existing and new business development opportunities, as well as managing Kamada's
existing strategic partner relationships.
"These important promotions reflect our
strategy focused on expanding our presence in the U.S. as a vertically-integrated specialty plasma company, including plasma collection
and commercialization of our recently expanded product portfolio," said Amir London, Kamada's Chief Executive Officer. "During
their time at Kamada, both Shavit and Boris demonstrated an unwavering dedication to the advancement of our business, including the successful
execution of many key initiatives and programs that are at the core of our strategic objectives. I look forward to their continued significant
contribution to our growth plans."
Ms. Beladev has been with Kamada for over 20 years
in increasingly senior positions, most recently as Director of Business Development. She also previously served in management roles at
the Company, responsible for International Sales, Key Accounts Management and Plasma Procurement. Since the establishment of Kamada Plasma
in early 2021, Ms. Beladev's extended responsibilities also included overseeing the operation of the Company's plasma collection center
in Beaumont, Texas, and the advance towards the opening of new centers.
Mr. Gorelik has been with Kamada for more than
two years, most recently as Director of Business Development. He has over 14 years of Business Development and M&A experience, most
of it in the pharmaceutical industry. Prior to joining Kamada, Mr. Gorelik was Senior Director of Global Business Development and Strategy
with Teva Pharmaceutical Industries, Ltd. Prior to his tenure at Teva, he served in various legal, M&A, and transaction services-related
roles in the Israeli law office of Goldfarb Seligman, as well as KPMG and Deloitte Israeli offices.
Kamada Ltd. (the "Company") is a vertically
integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products,
a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is focused on driving profitable
growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical
market. The Company's commercial products portfolio includes its developed and FDA approved products GLASSIA and KEDRAB
as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM , HEPAGAM B , VARIZIG and WINRHO SDF.
The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial
products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S.,
Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of
development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting
the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise
and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties
and have recently added 11 biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals,
are expected to be launched in Israel between the years 2022 and 2028. FIMI Opportunity Fund, the leading private equity investor in Israel,
is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.
Chief Financial Officer
LifeSci Advisors, LLC